| 2026-08-12 | Press release | Acadia Pharmaceuticals to Participate in the Canaccord Genuity 46th Annual Growth Conference |
| 2026-08-04 | Earnings deck | Presentation |
| 2026-08-04 | Press release | Acadia Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 4, 2026 |
| 2026-05-06 | Quarterly report | Acadia Pharmaceuticals Reports First Quarter 2026 Financial Results and Operating Overview of Q1 2026 Earnings, (opens i |
| 2026-05-06 | Presentation | Presentation
of Q1 2026, PDF file, (opens in new window) |
| 2026-02-25 | Presentation | Download PDF
(opens in new window) |
| 2026-01-13 | Press release | Acadia Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026 |
| 2026-01-13 | Presentation | Download PDF
(opens in new window) |
| 2025-11-05 | Quarterly report | Acadia Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operating Overview of Q3 2025 Earnings, (opens i |
| 2025-11-05 | Press release | Acadia Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operating Overview |
| 2025-08-06 | Quarterly report | Acadia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operating Overview of Q2 2025 Earnings, (opens |
| 2025-06-25 | Presentation | Download PDF
(opens in new window) |
| 2024-11-06 | Press release | Acadia Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operating Overview |
| 2024-08-06 | Press release | Acadia Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operating Overview |
| 2024-05-08 | Press release | Acadia Pharmaceuticals Reports First Quarter 2024 Financial Results and Operating Overview |
| 2024-02-27 | Press release | Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operating Overview |
| Press release | Acadia Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operating Overview |
| Press release | Acadia Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum |
| Press release | Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences |
| Press release | Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences |
| Press release | Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026 |
| Press release | Acadia Pharmaceuticals Reports Second Quarter 2026 Financial Results |
| Press release | Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operating Overview |
| Press release | Acadia Pharmaceuticals Reports First Quarter 2026 Financial Results and Reaffirms 2026 Financial Guidance |
| Press release | Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis |
| Press release | Acadia Pharmaceuticals Provides Update on Regulatory Submission for Trofinetide for the Treatment of Rett Syndrome in th |
| Press release | Acadia Pharmaceuticals Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference |
| Press release | Acadia Pharmaceuticals Appoints Jonathan M. Poole to its Board of Directors |
| Press release | Acadia Pharmaceuticals Appoints Carl Segerstrom as Chief People Officer |
| Press release | Acadia Pharmaceuticals Announces Plan to Request Re-Examination Following Negative CHMP Opinion for Trofinetide for the |
| Press release | Acadia Pharmaceuticals Announces Planned Year-End Retirement of Elizabeth H.Z. Thompson, Ph.D., Head of Research and Dev |
| Press release | Acadia Pharmaceuticals to Participate in Citi’s 2025 Global Healthcare Conference |
| Press release | Acadia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operating Overview |
| Press release | Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operating Overview |
| Press release | Acadia Pharmaceuticals Reports First Quarter 2025 Financial Results and Operating Overview |
| Press release | Acadia Pharmaceuticals Announces FDA Approval of DAYBUE® STIX (trofinetide) for Oral Solution, a New Powder Formulation |
| Press release | DAYBU® (trofinetide) Recommended for Approval in the European Union by CHMP |
| Press release | Acadia Pharmaceuticals to Present Data at the 2026 American Academy of Neurology (AAN) Annual Meeting |
| Press release | Acadia Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026 |
| Press release | Acadia Pharmaceuticals Announces DAYBUE® STIX (trofinetide) is Now Broadly Available in the United States for the Treatm |